BMS at ACTRIMS Forum 2022
Intended for U.S. scientific audiences only.
The 7th Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022 is an important opportunity to reinforce our commitment to scientific exchange on research and breakthroughs, with the goal of helping to preserve physical and cognitive functions in people living with multiple sclerosis (MS).
At ACTRIMS Forum 2022, Bristol Myers Squibb is presenting multiple abstracts with new research findings in appropriate patients with relapsing forms of MS. We look forward to showcasing new research and sharing progress with the MS community.
We are pursuing pathbreaking science and innovative solutions to potentially improve outcomes in MS. Read how our team is working to delay progression and prevent disability for individuals diagnosed with MS.
Hear from Diego Silva, vice president, Worldwide Medical, interim head of Immunology & Fibrosis and Cathy Trzaskawka (Traz), executive director, Bristol Myers Squibb Patient Advocacy, to learn how Bristol Myers Squibb's work in multiple sclerosis (MS) goes beyond the medicine, and how the company supports the entire community.
Learn more about our research in MS through the resources below.